Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MHB088C |
Synonyms | |
Therapy Description |
MHB088C is an antibody-drug conjugate (ADC) comprising a B7-H3 (CD276) antibody conjugated to a topoisomerase inhibitor, which potentially induces antitumor activity (J Clin Oncol 42, 2024 (suppl 16; abstr 3012)). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MHB088C | MHB 088C|MHB-088C | CD276 Antibody 16 | MHB088C is an antibody-drug conjugate (ADC) comprising a B7-H3 (CD276) antibody conjugated to a topoisomerase inhibitor, which potentially induces antitumor activity (J Clin Oncol 42, 2024 (suppl 16; abstr 3012)). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05652855 | Phase Ib/II | MHB088C | Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |